Log in

NASDAQ:SVRA - Savara Stock Price, Forecast & News

$2.15
-0.30 (-12.24 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$2.14
Now: $2.15
$2.43
50-Day Range
$1.91
MA: $2.39
$2.72
52-Week Range
$0.69
Now: $2.15
$11.96
Volume229,539 shs
Average Volume427,518 shs
Market Capitalization$109.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.01
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Read More
Savara logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-614-1848

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$4.48 per share
Book Value$2.47 per share

Profitability

Net Income$-78,170,000.00

Miscellaneous

EmployeesN/A
Market Cap$109.31 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.


Savara (NASDAQ:SVRA) Frequently Asked Questions

How has Savara's stock been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SVRA shares have decreased by 8.9% and is now trading at $2.15. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Savara?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.31. View Savara's earnings history.

What price target have analysts set for SVRA?

6 analysts have issued 1 year target prices for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they anticipate Savara's share price to reach $8.60 in the next year. This suggests a possible upside of 300.0% from the stock's current price. View analysts' price targets for Savara.

Has Savara been receiving favorable news coverage?

Media headlines about SVRA stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Savara earned a news impact score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutSavara.

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Who are Savara's key executives?

Savara's management team includes the following people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (12.45%), Farallon Capital Management LLC (11.71%), EcoR1 Capital LLC (3.48%), Point72 Asset Management L.P. (2.16%), Geode Capital Management LLC (1.06%) and Jacobs Levy Equity Management Inc. (0.81%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins, Robert N Neville and Yuri Pikover. View institutional ownership trends for Savara.

Which major investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and Bank of America Corp DE. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen, and Richard J Hawkins. View insider buying and selling activity for Savara.

Which major investors are buying Savara stock?

SVRA stock was bought by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, EcoR1 Capital LLC, Farallon Capital Management LLC, Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, Robert N Neville, and Yuri Pikover. View insider buying and selling activity for Savara.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $2.15.

How big of a company is Savara?

Savara has a market capitalization of $109.31 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis.  View additional information about Savara.

What is Savara's official website?

The official website for Savara is http://www.savarapharma.com/.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]


MarketBeat Community Rating for Savara (NASDAQ SVRA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  256 (Thanks for Voting!)
Underperform Votes:  279 (Thanks for Voting!)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is Put Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel